| INTRODUCTION
As the leading cause of mortality in the United States, CVD accounts for >787 000 deaths annually. 1 To define CV health, the American Heart Association (AHA) Life's Simple 7 (LS7) uses 7 metrics for clinicians: smoking, body mass index, physical activity level, healthy diet, total cholesterol, blood pressure, and fasting glucose. CV health in the United States is relatively poor, with only 3.3% of the population in ideal CV health among a survey of 356 411 adults. 2 Patients with poor LS7 metrics have traditional risk factors, contributing to an increase in lifetime CVD risk. Favorably impacting the development of these risk factors is the cornerstone for CVD primordial prevention.
By focusing on the cumulative effects of small population-based interventions, healthcare systems can effectively practice primordial prevention ( Figure 1 ).
To prevent CVD-related mortality, it is essential both to understand factors encompassing CV health and to systematically assess CV risk. Population-based CVD risk models that focus on traditional risk factors have been incorporated into guidelines to target primary prevention, attempting to shift the population toward better CV health. Despite these models, a sizeable gap in identifying asymptomatic individuals who develop CVD remains, as many have few, if any, traditional risk factors. 3 More than one-third of individuals with hypertension in the United States are undetected, and the Adult Treatment Panel III (ATP-III) approximates nearly 36 million patients needing treatment for elevated low-density lipoprotein cholesterol (LDL-C), whereas only 10 to 15 million are on lipid-lowering therapy. 3 Concomitantly, novel risk markers that underlie the pathogenesis of CVD are being investigated to potentially bridge this gap.
| GENERAL APPROACH TO RISK ASSESSMENT
Risk assessment begins with a detailed history and physical examination for the evaluation of traditional and nontraditional risk factors.
The use of a population-based risk calculator, such as the American
College of Cardiology (ACC)/AHA pooled cohort equations for ASCVD risk, should be employed to determine both absolute and lifetime CVD risk. 4 Based on this estimation, evidence-based guidelines can be utilized to determine individuals who would most likely benefit from statin and aspirin therapy and possibly more aggressive antihypertensive therapy. After determination of risk, a clinician-patient risk discussion should take place in which risk data are reviewed, evidence-based clinical guidelines are considered, and potential side effects to therapy are discussed with the patient as part of a shareddecision-making approach to care. 5 For patients in whom risk remains intermediate or uncertain, selective utilization of biomarkers, nontraditional risk factors, social determinants of health, and noninvasive measures of subclinical atherosclerosis can be applied to further inform treatment decisions ( Figure 2 ). 6 
| Traditional risk factors
In 1961, the coining of the term "risk factor" resulted from the identification of an initial set of traditional risk factors for coronary heart disease (CHD) in the Framingham Heart Study. 7 The important risk factors identified by the Framingham study were age (males ≥45 years or females ≥55 years), male sex, hypertension (HTN), dyslipidemia, smoking, and diabetes mellitus (DM). Over the past several decades, family history of premature ASCVD (age < 55 years for males and < 65 years for females) has been added. Human immunodeficiency virus is associated with several factors that contribute to increased CV risk. Accelerated atherosclerosis secondary to viral-mediated damage to the vascular endothelium is seen in both highly active antiretroviral therapy (HAART)-naïve and HAART-treated populations. 25 Increased expression of adhesion molecules (E-selectin and intracellular adhesion molecule 1) and inflammatory cytokines (tumor necrosis factor-α, interleukin-6) contribute to the pathogenesis of CVD. Patients who experience gestational HTN, preeclampsia, or other placental-mediated adverse events are often at risk of developing adverse CV risk factors after pregnancy. 27 The retrospective Cardiovascular Health After Maternal Placental Syndromes (CHAMPS) study cohort comprised 1.03 million women without CVD prior to pregnancy. 28 Adverse CV events were twice as common (hazard ratio: 2.0, 95% CI: 1.7-2.2) in women with preeclampsia, placental abruption, or placental infarction, and even higher when these maternal placental syndromes were associated with poor fetal growth or intrauterine fetal death. 28 Extensive burden of comorbidities, particularly affecting older populations, can affect CV risk. In patients with chronic obstructive pulmonary disease, underlying low-grade inflammation and oxidative stress have led to increased frequency of coronary artery disease when adjusting for other factors. 29 Patients with chronic liver disease associated with hepatic steatosis, including alcoholic liver disease, chronic hepatitis C infection, and nonalcoholic fatty liver disease, have increased CV risk. 30 Chronic kidney disease is a well-known contributor to CV morbidity and mortality. 31 This risk is inversely related to glomerular filtration rate and persists after adjusting for the traditional ASCVD risk factors. 32 In end-stage renal disease patients on dialysis, the rate of CV mortality is 10× to 20× higher than in the general population. 33 Other determinants of health, including social support, social networks, socioeconomic status, and mental health disorders, affect CVD risk. Individuals of lower socioeconomic status are at higher risk of traditional risk factors and participating in at-risk behaviors, including tobacco use. Rates of CVD significantly increase in countries with the greatest income inequality. 34 Individuals with major depression following an MI are at an elevated risk of death and future CV events. 35 Additionally, mental health disorders may serve as a barrier to adherence with cardiac medications. Hence, it is sometimes useful to screen for anxiety and depression using the Patient Health Questionnaire (PHQ-9) and the Generalized Anxiety Disorder scale (GAD-7). 36 
|

| Risk reclassification
Current guidelines stratify patients into low or high risk, with a group falling between the 2 categories. 4 However, patients stratified between the low-and high-risk groups, defined by an ASCVD pooled risk score of 5% to 7.5%, can have a highly variable comprehensive CVD risk. 37 This lack of clarity may cause difficulty for clinicians deciding between a conservative or more aggressive therapeutic approach. 37 Certain risk markers can augment the predictive value of population-based risk calculators and potentially reclassify individuals into a new risk category.
The C-statistic, a commonly reported standard for CVD riskprediction models, is a statistical tool to discriminate future adverse events from nonevents. 15 It ranges from 0.5 (the score applied is no better than random chance) to 1.0 (perfect discrimination) and can discern and rank the accuracy of one risk model over another. 15 A clinically significant increase in C-statistic for the coronary artery calcification (CAC) score typically seems to be around a threshold of ≥0.10. The C-statistic cannot say how much more likely an adverse event is to occur, and it cannot estimate the similarity between observed and estimated risk. 15 For instance, when examining multiple risk indices including the RRS and the ATP-III score in the Women's Health Initiative observational cohort, statistically significant differences in the C-statistic were seen. A C-statistic of 0.765 from the RRS vs a C-statistic of 0.757 from the ATP-III score (P = 0.04) suggested that the RRS is better discriminated against future adverse events compared with the ATP-III score. 38 Two important metrics to assess reclassification of risk are the net reclassification improvement (NRI) index and the integrative discrimination index (IDI). 39 The NRI indicates the quantity of reclassification occurring that is statistically significant, whereas the IDI determines how far subjects move on a continuum of predicted risk. carotid intima-media thickness, and brachial flow-mediated dilation. 40 Added to the FRS, the CAC had the highest improvement in accurately predicting risk compared with several other markers. The NRI effectively reclassified a net 25.5% of events to a higher risk category while reclassifying a net 40.4% of nonevents to a lower risk category. 40 Multiple risk indices within a certain population can be compared with the NRI and the IDI. For example, the FRS, ATP-III score and the RRS were applied to the multiethnic Women's Health Initiative observational cohort. 38 The RRS compared with the ATP-III score showed an improvement in predicting risk, with a 4% (P = 0.02) improvement in prediction of events based on the NRI (4.9%; 95% CI:
1.2-8.7, P = 0.010) and with improvement in discrimination of risk based on the IDI (4.1%; 95% CI: 2.7-5.7, P < 0.0001). hsCRP and low LDL-C randomized to statin therapy had a 20% risk reduction in all-cause mortality. 41 However, the cost-effectiveness of screening an asymptomatic population is unclear; moreover, there was no low-hsCRP group studied in JUPITER, and the Heart Outcomes Prevention Evaluation (HOPE-3) trial did not find that hsCRP values predicted benefit from statin use. High-sensitivity CRP has been incorporated into the RRS, a population-based risk calculator, which also incorporates family history of premature CVD. The 2013 ACC/AHA risk assessment guidelines recommend consideration of hsCRP measurement when the treatment decision is uncertain, with a level of ≥2 mg/L considered in support for upward risk stratification. 42 This cutpoint is challenging because African Americans tend to have significantly higher hsCRP levels than do Caucasians, and females tend to have higher baseline levels than do men. 43, 44 In the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial, canakinumab use led to a statistically significant reduction in hsCRP despite no lipid effects and a reduction in recurrent CV events, proving the inflammatory hypothesis of atherothrombosis. primary-prevention patients demonstrated that apoB was one of the best predictors of future CVD compared with other atherogenic measures. 49 The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS), composed of 6605 primary-prevention patients on statin therapy, showed apoB outperforming LDL-C in predicting future CV events. 50 In the CARDIA study comprising 2794 young adults without CVD, elevated apoB levels-despite a low non-HDL-C-predicted a nonzero CAC score at age 25. 51 The NLA specified apoB-containing lipoproteins as "a root cause of atherosclerosis"
contributing to clinical ASCVD events and recommends non-HDL-C as a primary target of therapy along with LDL-C. 48 Although simple, nonfasting non-HDL-C measurement is more predictive than LDL-C, the NRI for apoB has been marginal. Its identity as a separate laboratory test with higher cost and slower turnaround time has contributed to a lack of recommendation for routine use by the ACC/AHA. 4 
| HDL-C and HDL-C functionality
The use of HDL-C in large, prospective, observational studies suggest an inverse relationship between HDL-C levels and adverse CV events. 52 HDL-C is a central component of the ASCVD risk equation
and other risk calculators. 4 In post hoc analyses of the Treating to New Targets (TNT) study and JUPITER trial, there was no statistically significant association between HDL-C levels and adverse CV events in patients on statin therapy. 41 Moreover, increasing HDL-C, using therapy such as niacin on a background of statin use, does not appear to favorably affect CV outcomes. 53 HDL-C function at the molecular level may be a more robust predictor of adverse CV events than HDL-C levels. 52 Cholesterol efflux capacity, the most studied aspect of HDL-C functionality, involves the ability to transport cholesterol molecules from cells, like arterial macrophages, to the extracellular environment in a process termed reverse cholesterol transport. Within an atherosclerotic plaque, there is impaired cholesterol efflux due to dysfunctional apolipoprotein-A1. 54 A prospective cohort study involving 2924 individuals from the Dallas Heart Study evaluated the role of cholesterol efflux capacity in predicting adverse CV events. 54 Adjusting for traditional risk factors including HDL-C levels, there was a 67% risk reduction in adverse CV events in the highest quartile of efflux capacity, compared with the lowest. 54 However, measures of HDL-C function remain investigational and are not currently recommended by guidelines.
| NONINVASIVE MEASURES OF SUBCLINICAL ATHEROSCLEROSIS
| Ankle-brachial index
The ABI is utilized for the detection of PAD. Additionally, an abnormal ABI <0.9 is diagnostic of PAD and is associated with increased CV risk as well as atherosclerosis in other vascular territories. A meta-analysis involving 24 375 men and 20 377 females free of CVD showed that adding ABI to the FRS better predicted future coronary events, with a significant NRI for both men and women (4.3% and 9.6%, respectively). 55 The highest NRI values for both men and women were seen in those with 10-year CVD risk scores of 10% to 19%. ABI levels of <0.9 were associated with a > 2-fold increase in mortality, and borderline levels of 0.9 to 1.0 were still associated with nearly 2-fold increased risk. 56 Although the data suggest that ABI is effective for CV risk prediction independent of conventional assessment, intention to treat and as-treated analysis of quality-adjusted life-years, lifetime 58 These findings were corroborated in a prospective study of 687 treatment-naïve patients free of CVD. 59 However, if the expected 22% relative risk reduction per 1-mmol/L decrease in LDL-C from statin meta-analyses were applied, then clinical utility appeared severely limited in this population. 58 Among those deemed reasonable to treat based on ASCVD guidelines (10-year risk, 5%-7%), 40% had a CAC score of 0. 59 Collectively, this indicates a high incidence (40%-50%) of CAC scores of 0 in patients in whom statin therapy is being considered based on the current ACC/AHA guidelines, but who are unlikely to benefit based on their low risk of ASCVD and correspondingly high number needed to treat.
In the appropriate population, CAC detection is consistently supe- high-risk groups, as defined by guidelines, can potentially be further stratified into a higher-risk category if the CAC score is ≥300 or 75th
percentile, there is a family history of premature ASCVD, the CRP is ≥2 mg/L, and/or the ABI is <0.9. consideration should be given to use novel risk markers to improve detection of subclinical atherosclerosis.
